Abbott has received approval from the US Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small–cell lung cancer (NSCLC). The new Abbott Vysis ALK Break Apart FISH Probe test is designed to identify ALK-positive NSCLC patients for Pfizer’s approved NSCLC therapy, XALKORI® (crizotinib), an oral ALK inhibitor.
The Vysis ALK FISH test uses Abbott’s fluorescence in situ hybridization (FISH) technology to detect rearrangements of the ALK gene on the 2p23 chromosome. The diagnostic test offers clinicians a standardized, clinically validated method to identify patients more likely to benefit from the new therapy.
"The Abbott-Pfizer collaboration marks a breakthrough in the advancement of personalized medicine—and companion diagnostics specifically—that will help a subset of lung-cancer patients get treatment tailored to their unique genetic profile," said Stafford O’Kelly, head of Abbott’s molecular diagnostics business.
The simultaneous FDA approvals are expected to change clinical practice for the diagnosis and treatment of patients with NSCLC. The Abbott ALK test has been designed to identify those patients—about three to five percent of NSCLC patients—who would be candidates for the new drug.
Abbott’s Vysis ALK FISH test will be available to clinicians and pathologists through Abbott Molecular.